Semaglutide (Ozempic/Wegovy)

What is Semaglutide (Ozempic/Wegovy)?

GLP-1 receptor agonist. Reduces appetite and slows gastric emptying. FDA-approved for diabetes and obesity.

How Semaglutide (Ozempic/Wegovy) works

Binds GLP-1 receptors in the hypothalamus, pancreas, and gut to suppress appetite, slow gastric emptying, enhance insulin secretion, and reduce glucagon — producing sustained caloric deficit.

Benefits & uses

• Weight loss
• Blood sugar control
• Cardiovascular protection
• Appetite suppression
• Significant weight loss (~15% in trials)
• Strong blood-sugar control
• Appetite reduction
• Cardiovascular benefit (established)

Common uses: Weight loss, appetite control, blood glucose, cardiovascular risk reduction.

Semaglutide (Ozempic/Wegovy) dosage

Semaglutide (Ozempic/Wegovy) half-life

Semaglutide (Ozempic/Wegovy) side effects

Nausea, diarrhea, vomiting, constipation. Pancreatitis risk. Thyroid cancer concern (animal data).

Warnings & monitoring

• Prescription only
• GI side effects common — nausea, vomiting, diarrhea
• Black box warning: thyroid C-cell tumors in rodents
• Contraindicated in personal/family history of MTC
• Pancreatitis risk
• Muscle loss risk — ensure adequate protein + resistance training
• Titrate slowly — GI effects mostly first ~20 weeks, cause ~4% to discontinue
• Class risks: pancreatitis, gallbladder disease, gastroparesis
• Boxed warning: medullary thyroid carcinoma / MEN2 — contraindicated with that history
• Not for pregnancy

Preparation & storage

Semaglutide (Ozempic/Wegovy) interactions

• with Retatrutide

  Avoid · severe

  Both are GLP-1 receptor agonists; combining them dramatically increases nausea, vomiting, and gastrointestinal distress with no meaningful additive benefit.

  Timing: Do not use concurrently under any circumstances

• with Tirzepatide

  Avoid · severe

  Both are GLP-1 receptor agonists; concurrent use compounds GI toxicity and pancreatic stress with no additive efficacy.

  Timing: Never combine

• with Tirzepatide

  Avoid · severe

  These are both GLP-1 agonists from the same drug class; combining them offers no additional efficacy but substantially increases the risk of pancreatitis and GI complications.

  Timing: Do not use concurrently; choose one agent

• with AOD-9604

  Caution · moderate

  AOD-9604 is a GH fragment claimed to stimulate lipolysis; semaglutide reduces caloric intake via GLP-1 agonism. Stacking multiple fat-loss mechanisms may cause excessive caloric deficit and muscle loss.

  Timing: Avoid combining multiple fat-loss agents without medical supervision

• with AOD-9604

  Caution · mild

  Both compounds promote fat loss via different mechanisms (lipolysis vs appetite suppression) — additive effect can cause excessive caloric restriction and muscle catabolism.

  Timing: Start semaglutide dose at the lowest level when combining; monitor appetite closely

• with Berberine

  Caution · mild

  Both have hypoglycemic and GI effects; combined dosing amplifies nausea and risk of low glucose in lean users.

  Timing: Lower berberine to 500mg/day when on GLP-1

• with HGH Frag 176-191

  Caution · mild

  Both promote fat loss — HGH Frag via lipolysis inhibition, semaglutide via appetite suppression. Additive fat-loss effect is useful for cutting but risks excessive caloric restriction and lean mass loss.

  Timing: Monitor appetite and caloric intake closely; start HGH Frag at lowest dose

• with Insulin

  Caution · severe

  Both semaglutide and insulin lower blood glucose. Combining them without precise medical dosing guidance carries serious hypoglycemia risk. This combination requires a treating endocrinologist — not for unsupervised use.

  Timing: Never combine without continuous glucose monitoring and medical supervision

• with Peptide YY

  Caution · moderate

  Both compounds suppress appetite through different mechanisms. Combining them may cause excessive caloric restriction, nutritional deficiencies, and muscle wasting.

  Timing: Avoid stacking without medical guidance — additive appetite suppression

• with Tesofensine

  Caution · moderate

  Tesofensine raises BP/HR via NE/DA reuptake inhibition; combined with GLP-1 anorexia, can drive excessive lean mass loss and cardiovascular strain.

  Timing: Do not initiate simultaneously; separate by 4+ weeks if cycling

• with 5-Amino-1MQ

  Compatible

  5-Amino-1MQ activates AMPK and shifts NAD+ flux toward lipolysis — complementary to GLP-1 driven appetite suppression.

  Timing: Stack daily during fat-loss phase

• with BPC-157

  Compatible

  BPC-157 helps with the gastric emptying delay and gut irritation common during semaglutide dose escalation.

  Timing: BPC-157 250-500mcg daily during GLP-1 protocol

• with Testosterone

  Compatible · low

  Semaglutide used for weight management alongside TRT. Testosterone helps preserve muscle mass during weight loss induced by semaglutide-driven caloric restriction.

  Timing: GLP-1 agonist weekly; testosterone per TRT protocol

Commonly stacked with